Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

SNY vs. PFE: Which Stock Is the Better Value Option?

SNY vs. PFE: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights: Caterpillar, Walmart, McDonald's, Pfizer and Marsh & McLennan

The Zacks Analyst Blog Highlights: Caterpillar, Walmart, McDonald's, Pfizer and Marsh & McLennan

BioMarin (BMRN) Shares Down on Q1 Earnings & Sales Miss

BioMarin (BMRN) announces lower-than-expected earnings and revenues for the second quarter of 2019. It keeps its previously provided revenue guidance intact.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger

AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.

Mark Vickery headshot

Top Analyst Reports for Caterpillar, Walmart & McDonald's

Today's Research Daily features new research reports on 16 major stocks, including Caterpillar (CAT), Walmart (WMT) and McDonald's (MCD).

Exelixis (EXEL) Q2 Earnings & Sales Beat, Cabometyx Shines

Exelixis (EXEL) beats on earnings and sales in the second quarter, as lead drug Cabometyx continues momentum.

Is a Beat in Store for Nektar (NKTR) This Earnings Season?

The focus will be on Nektar Therapeutics' (NKTR) pipeline progress and launch plans for NKTR-181 when the company reports second-quarter results.

Economic and Earnings Date Deluge

Economic and Earnings Date Deluge

Mark Vickery headshot

Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More

Another busy day awaits investors here in the middle of summer: U.S.-China trade talks resume, Personal Income & Spending data is out and Q2 earnings continue their torrent.

Stock Market News For Jul 30, 2019

Ongoing U.S. and China trade negotiations and expectations around a Fed rate hike kept benchmarks on a tight leash on Monday.

Mylan (MYL) Beats on Q2 Earnings, Inks Deal with Pfizer

Mylan (MYL) gains from merger deal with a Pfizer unit and tops on earnings and sales in Q2.

Pfizer (PFE) Beats on Q2 Earnings, to Merge Upjohn With Mylan

Pfizer (PFE) beats estimates for second-quarter earnings but misses on sales. The company also lowers 2019 earnings and sales guidance.

What's in Store for Array BioPharma (ARRY) in Q4 Earnings?

Array BioPharma's (ARRY) Braftovi-Mektovi combination therapy is likely to drive fourth-quarter sales.

Pfizer (PFE) Q2 Earnings Top Estimates

Pfizer (PFE) delivered earnings and revenue surprises of 3.90% and -0.44%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Pfizer (PFE) This Earnings Season?

While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q2 sales, genericization of some older drugs will hurt the same.

Can Newer Drugs Help Amgen (AMGN) Beat on Earnings in Q2?

While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on second-quarter sales.

Kinjel Shah headshot

Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment

AstraZeneca (AZN), Roche (RHHBY), Bristol-Myers (BMY) and Glaxo (GSK) report Q2 results. FDA approves Lilly's (LLY) nasal glucagon to treat severe hypoglycemia.

Bristol-Myers (BMY) Beats on Q2 Earnings & Sales, Raises View

Bristol-Myers (BMY) beats both earnings and sales estimates in the second quarter, primarily on robust sales of Opdivo and Eliquis. However, pipeline setbacks are a concern.

Glaxo (GSK) Beats on Q2 Earnings, Shingrix Sales Strong

Glaxo (GSK) beats on earnings and sales in the second quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.

Zachary Stutler headshot

Can Pfizer's Q2 Earnings Help Boost PFE Stock in a Struggling Pharma Market?

Pfizer Inc. (PFE) is set to report its Q2 earnings results on Tuesday, July 30. Investors are hoping the report can boost PFE stock since it is down over 2% YTD.

Mitchell Moore headshot

What to Expect from Sanofi's (SNY) Q2 Earnings (Revised)

Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?

Mitchell Moore headshot

What to Expect from Sanofi's (SNY) Q2 Earnings

Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?

Merck (MRK) to Report Q2 Earnings: What's in the Cards?

Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive second-quarter sales. However, genericization of key drugs and increased competition are concerns.

Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pfizer (PFE) Gains But Lags Market: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $42.79, marking a +0.05% move from the previous day.